5Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics (NASDAQ:NMRA) and maintained a $23 price target.
August 07, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics and maintained a $23 price target.
The reiteration of a Buy rating and the maintenance of a $23 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100